Atlas Venture Fund Files Intent to Sell $6.7M in Kymera Therapeutics Stock
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (5.7× avg).
Summary
A significant institutional shareholder, Atlas Venture Opportunity Fund I, LP, has filed a Form 144 to sell approximately $6.69 million in Kymera Therapeutics stock, continuing a recent trend of distribution by Atlas Venture funds.
Key Events · Ownership and Investor Activity · KYMR
-
Intent to Sell Shares
Atlas Venture Opportunity Fund I, LP filed a Form 144 indicating its intent to sell 57,451 shares of Kymera Therapeutics common stock, valued at approximately $6.69 million.
-
Ongoing Distribution by Atlas Venture
This filing adds to a pattern of sales by Atlas Venture funds, which have collectively sold over $128 million in Kymera Therapeutics shares in the past three months. This includes a previous intent to sell from this same fund on June 22 for approximately $2 million.
-
Institutional Shareholder Activity
As a significant institutional shareholder, this intent to sell reflects a continued reduction in Atlas Venture's stake in the company.
Analysis · KYMR · Life Sciences
Atlas Venture Opportunity Fund I, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $6.69 million worth of Kymera Therapeutics common stock. This transaction is part of a broader pattern of distribution by Atlas Venture funds, which have collectively sold over $128 million in company shares in the past three months, including a previous intent to sell from this same fund on June 22. This ongoing selling activity by a major investor could create an overhang on the stock.
At the time of this filing, KYMR was trading at $108.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $36.65 to $130.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.